Cara Therapeutics discontinues neurological condition study as drug fails

(Reuters) -Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its oral drug did not show meaningful clinical benefit versus a placebo.

The company said its experimental oral version of the drug difelikefalin did not show a meaningful improvement in itching at any dose.

Notalgia paresthetica is a neurological condition that causes intense itching, burning or a tingling sensation near the shoulder blades.

(Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona and Shounak Dasgupta)